1
|
Aldhafeeri W, Habelrih F, Alshehri LA, Abdullah J, Alkutbi MM, Shah SM. Atypical Teratoid/Rhabdoid Tumor of the Sellar Region in an Adult Male: A Case Report. Cureus 2023; 15:e36599. [PMID: 37095822 PMCID: PMC10122536 DOI: 10.7759/cureus.36599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2023] [Indexed: 04/26/2023] Open
Abstract
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, fast-growing, aggressive tumor that is almost exclusively seen in the pediatric population; it has a poor prognosis despite aggressive treatment. Adult cases were thought to be exclusively of women, with a total of 23 cases reported worldwide. We herein report a case of a 35-year-old male who posed a unique clinical and diagnostic challenge. To the best of our knowledge, this is the third case of a male patient with sellar AT/RT in the world.
Collapse
Affiliation(s)
- Wafa Aldhafeeri
- Neurological Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | - Fehid Habelrih
- Neurological Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | - Lina A Alshehri
- Neurological Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | - Jamal Abdullah
- Neurological Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | | | - Syed M Shah
- Neurological Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| |
Collapse
|
2
|
Kieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, MacConaill LE, Garraway LA, Biegel JA. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer 2012; 59:1155-7. [PMID: 22997201 PMCID: PMC3538080 DOI: 10.1002/pbc.24315] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 08/14/2012] [Indexed: 12/13/2022]
Abstract
BACKGROUND Rhabdoid tumors (also called atypical teratoid/rhabdoid tumor (AT/RT) in the brain), are highly malignant, poor prognosis lesions arising in the kidneys, soft tissues, and central nervous system. Targeted therapy in this disease would benefit from advanced technologies detecting relevant actionable mutations. PROCEDURE Here we report on the evaluation of 25 tumors, all with known SMARCB1/INI1 alterations, for the presence of 983 different mutations in 115 oncogenes and tumor-suppressor genes using OncoMap, a mass spectrometric method of allele detection. RESULTS Other than mutations in SMARCB1, our results identified a single activating mutation in NRAS and complete absence of oncogenic mutations in all other genes tested. CONCLUSION The absence of mutations in canonical pathways critical for development and progression of adult cancers suggests that distinct mechanisms drive these highly malignant pediatric tumors. This may limit the therapeutic utility of available targeted therapies and require a refocusing toward developmental and epigenetic pathways.
Collapse
Affiliation(s)
- Mark W. Kieran
- Director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Hematology/ Oncology, 450 Brookline Avenue, Rm SW331, Boston, MA 02215 Tel (617) 632-4907 Fax (617) 632-4897 ,Address reprint requests to, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Hematology/Oncology, 450 Brookline Avenue, Rm SW331, Boston, MA 02215
| | - Charles W.M. Roberts
- Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Hematology/Oncology, 450 Brookline Avenue, Boston, MA 02215
| | - Susan N. Chi
- Dana-Farber Cancer Institute and Boston Children’s Hospital, Pediatric Hematology/Oncology, 450 Brookline Avenue, Boston, MA 02215
| | - Keith L. Ligon
- Dana-Farber Cancer Institute, Department of Medical Oncology, and Center for Molecular Oncologic Pathology, 450 Brookline Avenue, Rm JF200, Boston, MA 02115 Department of Pathology, Harvard Medical School, Brigham and Women’s Hospital and Boston Children’s Hospital
| | - Benjamin E. Rich
- Dana-Farber Cancer Institute, Department of Medical Oncology, and Center for Molecular Oncologic Pathology, 450 Brookline Avenue, Rm JF200, Boston, MA 02115 Department of Pathology, Harvard Medical School, Brigham and Women’s Hospital and Boston Children’s Hospital
| | - Laura E. MacConaill
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
| | - Levi A. Garraway
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215
| | - Jaclyn A. Biegel
- Department of Pediatrics, The Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, 1002 Abramson Research Center, 3615 Civic Center Boulevard, Philadelphia, PA 19104
| |
Collapse
|